52-year-old woman with a 1.8-cm breast mass
A 52-year-old woman comes to clinic 3 weeks after core biopsy of a 1.8-cm breast mass found on screening mammography. Pathology shows invasive ductal carcinoma that is estrogen receptor positive, progesterone receptor positive, and HER2 negative. She has no weight loss or bone pain. Exam shows a healing biopsy site without skin changes or palpable axillary nodes. She is premenopausal and otherwise healthy. Lumpectomy with sentinel node biopsy is planned. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
B
Explanation
Clinical Pearl:
Early-stage hormone receptor positive, HER2-negative breast cancer without symptoms or exam findings suggesting metastases is usually managed first with definitive local therapy, then adjuvant treatment guided by tumor biology and stage.
Explanation:
This patient has clinically localized breast cancer and is an appropriate candidate for breast-conserving therapy, consisting of lumpectomy with sentinel node evaluation followed by whole-breast radiation; because the tumor is hormone receptor positive, adjuvant endocrine therapy is also indicated. Current oncology practice does not recommend routine PET-CT or other metastatic staging imaging for asymptomatic patients with apparent stage I disease, so option A adds cost and false positives without improving care. Option C is wrong because trastuzumab is used for HER2-positive disease, and neoadjuvant systemic therapy is generally reserved for selected larger tumors, node-positive disease, or biologic subtypes where downstaging changes management. Option D is not the standard next step, as bilateral mastectomy does not improve survival for most average-risk patients with a unilateral small operable tumor and no stated genetic syndrome. Option E is inadequate because endocrine therapy does not replace definitive local treatment in an otherwise operable early breast cancer. The vignette is written so that breast conservation with appropriate adjuvant therapy is the clear guideline-based best answer.
See you tomorrow morning!